Resistance to EGFR Therapies in Colorectal Cancer

Speaker: Rodrigo Dienstmann

R. Dienstmann says that mechanisms of resistance to EGFR therapies are multiple at genomic level. Irrespective of tumour type, if there is downstream activation of the pathway with MAPK mutation, KRAS, NRAS, BRAF, it is unlikely to benefit from upstream EGFR inhibition. It is expected that combination treatment with MEK inhibitors and a boost with immunotherapy increase efficacy of anti-EGFR inhibition.

Discussion Points

  • Mechanisms of resistance and implications for treatment
  • How to circumvent resistance to EGFR therapy in colorectal cancer
  • What is similar and what is different in comparison to EGFR targeting in other solid tumours